Advanced Enzyme Technologies Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹215 Cr +16.2% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
AE

Advanced Enzyme Technologies Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Advanced Enzyme Technologies Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹203Cr
+21.6% YoY
+18% QoQ
Net profit
₹45Cr
+66.7% YoY
+4.7% QoQ
Margin
31%
+4 pp YoY
+2 pp QoQ

What the Q4 FY26 call signalled

2 of 4 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Order bookOrder book rising
Price₹300
Market cap₹3.7K Cr
P/E24.0

The short version

The company expects steady double-digit growth in overall sales/revenue, driven by broad-based growth across human nutrition, animal nutrition, and other segments. The company is confident about sustaining steady growth momentum into the coming years, supported by broader market adoption of enzymes across pharmaceuticals, nutraceuticals, and biotechnology sectors.

From Advanced Enzyme Technologies Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • The company expects steady double-digit growth in overall sales/revenue, driven by broad-based growth across human nutrition, animal nutrition, and other segments. (Page 13, 14)
  • Moderate growth is anticipated from emerging areas like biocatalysis and new products under trial, with some launches expected this year. (Page 13)
  • U.S. business is under pressure with a challenging market environment, but the company is working on regulatory registrations and increasing market share for future growth. (Pages 20, 8)
  • Indian business showed strong growth, expected to continue, fueled by volume growth and some potential price increases. (Pages 8, 9)

2 more points from Advanced Enzyme Technologies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • The company plans an incremental capital expenditure (CapEx) of about INR 50 crores this year.
  • Overall R&D CapEx is expected to be around INR 130 crores, including INR 50 million increase in R&D revenue expenditure.
  • Infrastructure buildup is largely in place, allowing for a 50% capacity increase in fermentation capacity without immediate expansion.
  • A capacity expansion decision will be taken after September; some incremental capacity expansion may occur in a subsidiary.
  • The new R&D facility is expected to be operational in the second half of the year, aiming to triple R&D capacity eventually.

2 more points from Advanced Enzyme Technologies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
From the discussion, some relevant insights include: - The company is focusing on steady growth across segments including human nutrition, animal nutrition, and probiotics. - There is an emphasis on expanding the U.S. market despite challenges and changing market dynamics. - Moderate growth is expected in new product areas such as biocatalysis and proprietary solutions using probiotics. - The company maintains a strong R&D pipeline with active product trials underway.

2 more points from Advanced Enzyme Technologies Ltd's call on order book

Create a free account to keep reading this call

Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Advanced Enzyme Technologies Ltd Q4 FY26 results — key figures

Advanced Enzyme Technologies Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue203167+21.6%172+18%
Operating profit (EBITDA)6346+37%49+28.6%
Operating margin31%27%+4 pp29%+2 pp
Profit before tax6043+39.5%58+3.4%
Net profit (PAT)4527+66.7%43+4.7%
EPS (₹)3.842.37+62%3.80+1.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹215 Cr, net profit ₹51 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Advanced Enzyme Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Advanced Enzyme Technologies Ltd Q4 FY26 results?

The company expects steady double-digit growth in overall sales/revenue, driven by broad-based growth across human nutrition, animal nutrition, and other segments. The company is confident about sustaining steady growth momentum into the coming years, supported by broader market adoption of enzymes across pharmaceuticals, nutraceuticals, and biotechnology sectors.

What is Advanced Enzyme Technologies Ltd share price analysis?

Advanced Enzyme Technologies Ltd currently shows a below-average growth signal. The stock trades at a P/E of 24.0 with a market cap of ₹3,726 Cr. Investors should review the full earnings analysis for detailed insights.

Is Advanced Enzyme Technologies Ltd planning capital expenditure?

The company plans an incremental capital expenditure (CapEx) of about INR 50 crores this year.

Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.